MX347318B - Ratones que expresan una cadena ligera hibrida de inmunoglobulina. - Google Patents

Ratones que expresan una cadena ligera hibrida de inmunoglobulina.

Info

Publication number
MX347318B
MX347318B MX2015008806A MX2015008806A MX347318B MX 347318 B MX347318 B MX 347318B MX 2015008806 A MX2015008806 A MX 2015008806A MX 2015008806 A MX2015008806 A MX 2015008806A MX 347318 B MX347318 B MX 347318B
Authority
MX
Mexico
Prior art keywords
sequences
mice
light chain
express
human
Prior art date
Application number
MX2015008806A
Other languages
English (en)
Inventor
J Murphy Andrew
Macdonald Lynn
A Hosiawa Karolina
Gurer Cagan
Stevens Sean
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX347318B publication Critical patent/MX347318B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Abstract

La presente invención se refiere a ratones modificados genéticamente que expresan secuencias variables ? humanas (hV?), incluyendo ratones que expresan secuencias hV? de un locus endógeno de la cadena ligera ? de ratón, ratones que expresan secuencias hV? de un locus endógeno de la cadena ligera ? de ratón, y ratones que expresan secuencias hV? a partir de un transgene o un episoma en donde la secuencia hV? está unida a una secuencia constante de ratón. Se proporcionan ratones que son una fuente de secuencias variables ? humanas mutadas somáticamente útiles para producir proteínas de unión a antígenos. Se proporcionan composiciones y métodos para producir proteínas de unión a antígenos que comprenden secuencias variables ?. humanas, que incluyen anticuerpos humanos.
MX2015008806A 2010-06-22 2011-06-22 Ratones que expresan una cadena ligera hibrida de inmunoglobulina. MX347318B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35731710P 2010-06-22 2010-06-22
US35731410P 2010-06-22 2010-06-22
PCT/US2011/041370 WO2011163314A1 (en) 2010-06-22 2011-06-22 Hybrid light chain mice

Publications (1)

Publication Number Publication Date
MX347318B true MX347318B (es) 2017-04-21

Family

ID=44509861

Family Applications (6)

Application Number Title Priority Date Filing Date
MX2015008806A MX347318B (es) 2010-06-22 2011-06-22 Ratones que expresan una cadena ligera hibrida de inmunoglobulina.
MX2015009162A MX347322B (es) 2010-06-22 2011-06-22 Ratones que expresan una cadena ligera con regiones constantes de raton y variables lambda humanas.
MX2012015300A MX336344B (es) 2010-06-22 2011-06-22 Ratones que expresan una cadena ligera con regiones constantes de raton y variables lambda humanas.
MX2015008807A MX348942B (es) 2010-06-22 2011-06-22 Ratones que expresan una cadena ligera hibrida de inmunoglobulina.
MX2012015298A MX2012015298A (es) 2010-06-22 2011-06-22 Ratones con cadena ligera hibrida.
MX2022002117A MX2022002117A (es) 2010-06-22 2012-12-19 Ratones que expresan una cadena ligera hibrida de inmunoglobulina.

Family Applications After (5)

Application Number Title Priority Date Filing Date
MX2015009162A MX347322B (es) 2010-06-22 2011-06-22 Ratones que expresan una cadena ligera con regiones constantes de raton y variables lambda humanas.
MX2012015300A MX336344B (es) 2010-06-22 2011-06-22 Ratones que expresan una cadena ligera con regiones constantes de raton y variables lambda humanas.
MX2015008807A MX348942B (es) 2010-06-22 2011-06-22 Ratones que expresan una cadena ligera hibrida de inmunoglobulina.
MX2012015298A MX2012015298A (es) 2010-06-22 2011-06-22 Ratones con cadena ligera hibrida.
MX2022002117A MX2022002117A (es) 2010-06-22 2012-12-19 Ratones que expresan una cadena ligera hibrida de inmunoglobulina.

Country Status (31)

Country Link
US (21) US9012717B2 (es)
EP (7) EP2480676B1 (es)
JP (15) JP6009441B2 (es)
KR (16) KR101975884B1 (es)
CN (4) CN104404050B (es)
AU (1) AU2011271046B2 (es)
BR (3) BR112012033248A2 (es)
CA (2) CA2803864C (es)
CY (5) CY1117537T1 (es)
DK (5) DK2480675T3 (es)
ES (5) ES2575223T3 (es)
HK (4) HK1168384A1 (es)
HR (5) HRP20160497T1 (es)
HU (5) HUE036597T2 (es)
IL (11) IL300712A (es)
LT (4) LT3034608T (es)
ME (5) ME02902B (es)
MX (6) MX347318B (es)
MY (6) MY195217A (es)
NO (1) NO2905338T3 (es)
NZ (6) NZ605758A (es)
PL (5) PL3034608T3 (es)
PT (5) PT2905338T (es)
RS (5) RS54891B1 (es)
RU (3) RU2601297C2 (es)
SG (4) SG186391A1 (es)
SI (5) SI2480675T1 (es)
SM (3) SMT201600212B (es)
TR (1) TR201905992T4 (es)
WO (2) WO2011163311A1 (es)
ZA (5) ZA201300062B (es)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP3889265A1 (en) 2008-09-30 2021-10-06 Ablexis, LLC Transgenic mice for the production of chimeric antibodies
CN112690250B (zh) 2008-12-18 2024-03-08 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
DK3028565T3 (da) 2009-07-08 2017-11-13 Kymab Ltd Dyremodeller og terapeutiske molekyler
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
ES2603559T5 (es) 2010-02-08 2021-02-22 Regeneron Pharma Cadena ligera común de ratón
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
KR102004106B1 (ko) 2010-03-31 2019-07-25 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
PL3034608T3 (pl) * 2010-06-22 2019-08-30 Regeneron Pharmaceuticals, Inc. Myszy wykazujące ekspresję hybrydowego łańcucha lekkiego immunoglobuliny z ludzkim regionem zmiennym
RU2580017C2 (ru) 2010-07-26 2016-04-10 Трианни, Инк. Трансгенные животные и способы применения
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
MX2018014787A (es) 2010-08-02 2023-02-14 Regeneron Pharma Ratones que producen proteinas de union que comprenden dominios vl.
ES2872081T3 (es) 2011-08-05 2021-11-02 Regeneron Pharma Ratones con cadena ligera universal humanizada
EP4091442A1 (en) 2011-09-19 2022-11-23 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
JP2014531452A (ja) * 2011-09-19 2014-11-27 カイマブ・リミテッド 動物、レパートリーおよび方法
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
JP6327750B2 (ja) * 2011-12-20 2018-05-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化軽鎖マウス
CA2865644A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
PL2825037T4 (pl) 2012-03-16 2020-03-31 Regeneron Pharmaceuticals, Inc. Gryzonie eksprymujące sekwencje immunoglobuliny wrażliwej na pH
KR102228296B1 (ko) 2012-03-16 2021-03-17 리제너론 파마슈티칼스 인코포레이티드 히스티딘 공학처리된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-사람 동물
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
JP2015512635A (ja) 2012-03-28 2015-04-30 カイマブ・リミテッド クラススイッチした完全ヒト抗体の発現のためのトランスジェニック非−ヒト脊椎動物
SG11201505383UA (en) 2013-02-20 2015-08-28 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
KR102295842B1 (ko) * 2013-03-13 2021-08-31 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 경쇄 레퍼토리를 발현하는 마우스
US9980470B2 (en) 2013-03-14 2018-05-29 Erasmus University Medical Center Antibody production
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
RU2019121863A (ru) * 2013-09-18 2019-08-29 Регенерон Фармасьютикалз, Инк. Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения
SG11201602236SA (en) 2013-10-01 2016-04-28 Kymab Ltd Animal models and therapeutic molecules
EP3092007A4 (en) * 2014-01-10 2017-06-07 Allermabs Co. Ltd. Transgenic animals capable of producing humanized ige at much higher levels than mouse ige
EP3119811B1 (en) 2014-03-21 2019-10-30 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
JP6636498B2 (ja) 2014-03-21 2020-01-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 単一ドメイン結合タンパク質を作る非ヒト動物
KR101923326B1 (ko) 2014-06-06 2018-11-29 브리스톨-마이어스 스큅 컴퍼니 글루코코르티코이드-유도 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도
US20160081314A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric Antigen Receptors
AU2015327819B2 (en) 2014-10-03 2021-07-01 Massachusetts Institute Of Technology Antibodies that bind ebola glycoprotein and uses thereof
UY36404A (es) 2014-11-21 2016-06-01 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware ANTICUERPOS MONOCLONALES (Ab) COMO DETECTORES DE CD73 E INHIBIDORES DE SU ACTIVIDAD ENZIMÁTICA, Y COMPOSICIONES QUE LOS CONTIENEN
JP6738348B2 (ja) 2014-12-19 2020-08-12 リジェネサンス ベスローテン フェンノートシャップ ヒトｃ６に結合する抗体およびその使用
EP4249066A3 (en) 2014-12-23 2023-11-22 Bristol-Myers Squibb Company Antibodies to tigit
TR201904686T4 (tr) 2015-02-05 2019-05-21 Basf Se Bi̇r bi̇ri̇nci̇ isi transfer çevri̇mi̇ne ve bi̇r i̇ki̇nci̇ isi transfer çevri̇mi̇ne sahi̇p olan güneş enerji̇si̇ santrali̇
JP2018508224A (ja) * 2015-03-19 2018-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗原を結合する軽鎖可変領域を選択する非ヒト動物
MY188049A (en) 2015-05-29 2021-11-12 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof
EP3313886A1 (en) 2015-06-29 2018-05-02 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
CN105274116B (zh) * 2015-10-21 2020-09-29 重庆金迈博生物科技有限公司 一种制备人源化抗体的核酸分子及其应用
EP3377532B1 (en) 2015-11-19 2022-07-27 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2017095939A1 (en) 2015-12-03 2017-06-08 Trianni, Inc. Enhanced immunoglobulin diversity
KR20180104149A (ko) 2016-02-04 2018-09-19 트리아니, 인코포레이티드 면역글로불린의 증대된 생성
KR20230038311A (ko) 2016-03-04 2023-03-17 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
CN109071655B (zh) 2016-03-04 2022-08-12 洛克菲勒大学 具有增强的激动剂活性的cd40的抗体
MX2018013072A (es) 2016-05-09 2019-03-21 Squibb Bristol Myers Co Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
KR20240016444A (ko) 2016-05-20 2024-02-06 리제너론 파마슈티칼스 인코포레이티드 다중 가이드 RNAs를 이용한 면역학적 내성 파괴 방법
KR102598120B1 (ko) 2016-06-03 2023-11-07 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
US20170371963A1 (en) * 2016-06-27 2017-12-28 Facebook, Inc. Systems and methods for identifying matching content
TWI780057B (zh) 2016-07-14 2022-10-11 美商必治妥美雅史谷比公司 針對tim3之抗體及其用途
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
AU2017343778A1 (en) 2016-10-13 2019-05-02 Massachusetts Institute Of Technology Antibodies that bind Zika virus envelope protein and uses thereof
RS60886B1 (sr) 2016-11-04 2020-11-30 Regeneron Pharma Ne-humane životinje koje imaju konstruisani lokus imunoglobulinskog lamba lakog lanca
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
PL3720279T3 (pl) 2017-12-05 2023-01-16 Regeneron Pharmaceuticals, Inc. Myszy posiadające zmodyfikowany sposobami inżynierii łańcuch lekki lambda immunoglobuliny oraz ich zastosowania
JP7358361B2 (ja) 2018-01-12 2023-10-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
US11242393B2 (en) 2018-03-23 2022-02-08 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
MX2020009989A (es) 2018-03-24 2020-10-14 Regeneron Pharma Animales no humanos geneticamente modificados para generar anticuerpos terapeuticos contra complejos peptidos-mhc, metodos de elaboracion y usos de estos.
SG11202008620VA (en) 2018-03-26 2020-10-29 Regeneron Pharma Humanized rodents for testing therapeutic agents
KR102480493B1 (ko) * 2018-06-08 2022-12-21 크리스탈 바이오사이언스 주식회사 동일한 경쇄 i을 갖는 다양한 항체를 생산하기 위한 트랜스제닉 동물
WO2019241692A1 (en) 2018-06-14 2019-12-19 Regeneron Pharmaceuticals, Inc. Non-human animals capable of dh-dh rearrangement in the immunoglobulin heavy chain coding sequences
WO2020085011A1 (ja) 2018-10-26 2020-04-30 ビークルエナジージャパン株式会社 電池制御装置
JP2022509942A (ja) 2018-11-16 2022-01-25 ブリストル－マイヤーズ スクイブ カンパニー 抗ｎｋｇ２ａ抗体およびその使用
AU2020210635A1 (en) 2019-01-22 2021-08-19 Bristol Myers Squibb Company Antibodies against IL-7R alpha subunit and uses thereof
MX2021009855A (es) 2019-02-22 2021-09-10 Regeneron Pharma Roedores que tienen canales de sodio modificados geneticamente y metodos de uso de los mismos.
MX2021014893A (es) 2019-06-05 2022-03-11 Regeneron Pharma Animales no humanos que tienen un repertorio de cadena ligera lambda limitado expresado a partir del locus kappa y usos de estos.
CN114554841A (zh) * 2019-07-01 2022-05-27 特里安尼公司 转基因哺乳动物及其使用方法
JP2023504172A (ja) 2019-12-02 2023-02-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
KR20230024822A (ko) * 2020-06-25 2023-02-21 주식회사 휴맵 이형접합성 형질전환 동물
JP2023540808A (ja) 2020-09-11 2023-09-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗原特異的抗体の同定及び産生
CN116848254A (zh) 2020-12-16 2023-10-03 瑞泽恩制药公司 表达人源化Fcα受体的小鼠
CA3197426A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
TW202241934A (zh) 2020-12-23 2022-11-01 美商再生元醫藥公司 編碼錨定修飾抗體之核酸及其用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0580737B1 (en) 1991-04-10 2004-06-16 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
IL109168A0 (en) * 1993-04-01 1994-06-24 Univ Columbia A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
WO1998024893A2 (en) * 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
GB9823930D0 (en) * 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
KR100857943B1 (ko) * 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
GB0031284D0 (en) * 2000-12-21 2001-01-31 Ks Biomedix Ltd High affinity antibodies
CA2508763C (en) * 2001-05-11 2012-01-24 Kirin Beer Kabushiki Kaisha Human antibody producing mouse and method for producing human antibody using the same
GB0115256D0 (en) * 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
ES2645563T3 (es) * 2001-11-30 2017-12-05 Amgen Fremont Inc. Animales transgénicos que portan genes de cadena ligera de Ig humana
US20030217171A1 (en) 2002-05-17 2003-11-20 Von Stuermer Wolfgang R. Self-replicating and self-installing software apparatus
WO2005007696A2 (en) * 2003-07-15 2005-01-27 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
CN1605628A (zh) * 2003-09-03 2005-04-13 中国疾病预防控制中心病毒病预防控制所 Cho细胞生产的人源抗甲肝病毒基因工程抗体
RU2398777C2 (ru) * 2004-08-05 2010-09-10 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТАГОНИСТЫ, НАПРАВЛЕННЫЕ ПРОТИВ c-met
AU2005295269B2 (en) 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
KR100971497B1 (ko) * 2004-12-29 2010-07-21 주식회사유한양행 인간 종양괴사인자-알파에 특이적으로 결합하는 인간화항체
US7910798B2 (en) 2006-03-31 2011-03-22 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
CN101501073A (zh) * 2006-08-22 2009-08-05 G2英弗勒美欣私人有限公司 抗体制备方法
HUE054090T2 (hu) 2006-10-02 2021-08-30 Regeneron Pharma A humán IL-4 receptorral szemben nagy affinitást mutató humán antitestek
US7864492B2 (en) 2006-10-31 2011-01-04 Siemens Industry, Inc. Systems and methods for arc fault detection
DE102007045897A1 (de) 2007-09-26 2009-04-09 Carl Zeiss Microimaging Gmbh Verfahren zur mikroskopischen dreidimensionalen Abbildung einer Probe
EP2271758B1 (en) * 2008-04-14 2018-09-12 Innovative Targeting Solutions Inc. Sequence diversity generation in immunoglobulins
EP2288623B1 (en) * 2008-05-23 2013-07-10 Ablexis, LLC Method of generating single vl domain antibodies in transgenic animals
EP3889265A1 (en) 2008-09-30 2021-10-06 Ablexis, LLC Transgenic mice for the production of chimeric antibodies
CN112690250B (zh) * 2008-12-18 2024-03-08 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
DK3028565T3 (da) 2009-07-08 2017-11-13 Kymab Ltd Dyremodeller og terapeutiske molekyler
ES2603559T5 (es) * 2010-02-08 2021-02-22 Regeneron Pharma Cadena ligera común de ratón
NZ605966A (en) 2010-06-17 2015-04-24 Kymab Ltd Animal models and therapeutic molecules
PL3034608T3 (pl) 2010-06-22 2019-08-30 Regeneron Pharmaceuticals, Inc. Myszy wykazujące ekspresję hybrydowego łańcucha lekkiego immunoglobuliny z ludzkim regionem zmiennym

Also Published As

Publication number Publication date
RS55042B1 (sr) 2016-12-30
JP2017006152A (ja) 2017-01-12
MX2022002117A (es) 2022-03-17
KR20200064166A (ko) 2020-06-05
KR20190014576A (ko) 2019-02-12
CN104342455A (zh) 2015-02-11
US9066502B2 (en) 2015-06-30
US20150089680A1 (en) 2015-03-26
SG10201504568YA (en) 2015-07-30
JP6073441B2 (ja) 2017-02-01
KR20190014578A (ko) 2019-02-12
DK2480675T3 (en) 2016-08-01
HRP20160794T1 (hr) 2016-08-12
US20120070861A1 (en) 2012-03-22
KR101934852B1 (ko) 2019-01-04
US9226484B2 (en) 2016-01-05
CA2804311C (en) 2017-09-12
US9029628B2 (en) 2015-05-12
SI2568049T1 (sl) 2016-10-28
JP6963542B2 (ja) 2021-11-10
RU2013102596A (ru) 2014-07-27
PT3034608T (pt) 2019-05-28
SMT201600229B (es) 2016-08-31
BR112012032991A8 (pt) 2020-09-29
CN103068994A (zh) 2013-04-24
KR20180135996A (ko) 2018-12-21
KR102193823B1 (ko) 2020-12-22
JP6009441B2 (ja) 2016-10-19
US20150176002A1 (en) 2015-06-25
KR101970944B1 (ko) 2019-04-23
KR20190049932A (ko) 2019-05-09
US9206261B2 (en) 2015-12-08
KR20130027555A (ko) 2013-03-15
DK3034608T3 (da) 2019-05-06
JP2016010417A (ja) 2016-01-21
MY157477A (en) 2016-06-15
IL259965A (en) 2018-07-31
US20200239837A1 (en) 2020-07-30
HUE029692T2 (en) 2017-03-28
NZ707200A (en) 2016-04-29
SMT201600213B (it) 2016-08-31
ES2575223T3 (es) 2016-06-27
IL264634B (en) 2019-09-26
US20140137275A1 (en) 2014-05-15
NZ707198A (en) 2016-04-29
BR112012033248A2 (pt) 2017-11-28
HRP20190807T1 (hr) 2019-08-23
KR101975884B1 (ko) 2019-05-10
LT3034608T (lt) 2019-05-27
PL2480676T3 (pl) 2016-10-31
JP2018023403A (ja) 2018-02-15
HK1183321A1 (zh) 2013-12-20
MY165287A (en) 2018-03-21
NO2905338T3 (es) 2017-12-30
IL269078B (en) 2021-05-31
IL282872B (en) 2022-04-01
US20130323790A1 (en) 2013-12-05
JP2023133554A (ja) 2023-09-22
WO2011163314A1 (en) 2011-12-29
ME02902B (me) 2018-04-20
EP2568049A1 (en) 2013-03-13
ZA201506598B (en) 2017-03-29
US20120073004A1 (en) 2012-03-22
WO2011163311A1 (en) 2011-12-29
EP2480675A1 (en) 2012-08-01
ZA201404601B (en) 2016-02-24
ES2570131T3 (es) 2016-05-17
ZA201404600B (en) 2015-09-30
EP2480676B1 (en) 2016-04-06
ME02442B (me) 2016-09-20
PL2568049T3 (pl) 2017-03-31
MY195212A (en) 2023-01-11
KR20190142436A (ko) 2019-12-26
US9394373B2 (en) 2016-07-19
SMT201600212B (it) 2016-08-31
US9850462B2 (en) 2017-12-26
MX347322B (es) 2017-04-21
US20150173332A1 (en) 2015-06-25
BR112012032991B1 (pt) 2021-08-10
MX2012015300A (es) 2013-05-01
US9844212B2 (en) 2017-12-19
AU2011271043A1 (en) 2013-01-31
HK1226766A1 (zh) 2017-10-06
IL291301A (en) 2022-05-01
JP2013532974A (ja) 2013-08-22
CN104342455B (zh) 2017-05-31
JP6243384B2 (ja) 2017-12-06
ME02440B (me) 2016-09-20
ME03386B (me) 2020-01-20
JP2018201528A (ja) 2018-12-27
RS56589B1 (sr) 2018-02-28
US20160060359A1 (en) 2016-03-03
MX2012015298A (es) 2013-05-01
US9206263B2 (en) 2015-12-08
CN104404050A (zh) 2015-03-11
NZ605758A (en) 2014-08-29
AU2011271043A8 (en) 2016-01-21
JP7236409B2 (ja) 2023-03-09
RS58736B1 (sr) 2019-06-28
US9012717B2 (en) 2015-04-21
KR102118565B1 (ko) 2020-06-03
US20190153384A1 (en) 2019-05-23
EP3205726A1 (en) 2017-08-16
JP6545773B2 (ja) 2019-07-17
US9399683B2 (en) 2016-07-26
CN103068994B (zh) 2016-01-20
IL255179A0 (en) 2017-12-31
JP2020062061A (ja) 2020-04-23
ES2576928T3 (es) 2016-07-12
BR112012032991A2 (pt) 2015-10-06
HRP20171666T1 (hr) 2017-12-15
KR102059909B1 (ko) 2019-12-27
MY195214A (en) 2023-01-11
MX348942B (es) 2017-07-04
IL282872A (en) 2021-06-30
US9150662B2 (en) 2015-10-06
AU2011271046B2 (en) 2015-10-01
IL223720A (en) 2017-05-29
IL244450A0 (en) 2016-04-21
JP5988969B2 (ja) 2016-09-07
JP2016010415A (ja) 2016-01-21
RU2016119423A (ru) 2018-11-07
MX336344B (es) 2016-01-15
JP2022066449A (ja) 2022-04-28
MY195217A (en) 2023-01-11
US20160057979A1 (en) 2016-03-03
CY1117692T1 (el) 2017-05-17
SG10201504324UA (en) 2015-07-30
US20130326647A1 (en) 2013-12-05
BR122020013427B1 (pt) 2021-08-03
AU2011271043B2 (en) 2015-10-01
DK2480676T3 (en) 2016-06-20
IL300712A (en) 2023-04-01
EP3456832A1 (en) 2019-03-20
KR20180135997A (ko) 2018-12-21
KR102211911B1 (ko) 2021-02-05
SI2905338T1 (sl) 2017-12-29
ES2646052T3 (es) 2017-12-11
PL3034608T3 (pl) 2019-08-30
HUE029691T2 (en) 2017-03-28
US20170258059A1 (en) 2017-09-14
RU2013102595A (ru) 2014-07-27
KR101945352B1 (ko) 2019-02-07
HUE044001T2 (hu) 2019-09-30
RU2601297C2 (ru) 2016-10-27
PT2480676E (pt) 2016-06-09
AU2011271046A1 (en) 2013-01-31
CN103068993B (zh) 2016-01-06
TR201905992T4 (tr) 2019-05-21
CY1119478T1 (el) 2018-03-07
CA2803864C (en) 2017-05-16
HRP20160497T1 (hr) 2016-07-15
US9206262B2 (en) 2015-12-08
KR20200143511A (ko) 2020-12-23
SI2480676T1 (sl) 2016-10-28
EP3034608A1 (en) 2016-06-22
DK2568049T3 (en) 2016-08-01
NZ627119A (en) 2015-05-29
KR102266097B1 (ko) 2021-06-18
PT2905338T (pt) 2017-11-10
NZ605751A (en) 2014-10-31
MY194456A (en) 2022-11-30
EP2480675B1 (en) 2016-04-06
JP2020128440A (ja) 2020-08-27
SG186390A1 (en) 2013-01-30
PL2480675T3 (pl) 2017-03-31
PT2568049T (pt) 2016-07-11
JP2013531501A (ja) 2013-08-08
CA2803864A1 (en) 2011-12-29
US20150246976A1 (en) 2015-09-03
CN104404050B (zh) 2018-06-08
IL223719A (en) 2016-10-31
KR20210134424A (ko) 2021-11-09
ZA201300063B (en) 2014-09-25
JP6341972B2 (ja) 2018-06-13
AU2011271043A9 (en) 2015-10-01
HK1170766A1 (zh) 2013-03-08
SG186391A1 (en) 2013-01-30
ME02444B (me) 2016-09-20
US20150320023A1 (en) 2015-11-12
KR20130121814A (ko) 2013-11-06
LT2568049T (lt) 2016-10-10
CY1122877T1 (el) 2021-05-05
SI2480675T1 (sl) 2016-08-31
KR102001430B1 (ko) 2019-07-18
IL291301B2 (en) 2023-07-01
US9006511B2 (en) 2015-04-14
EP2480676A1 (en) 2012-08-01
NZ626979A (en) 2015-05-29
LT2480675T (lt) 2016-10-10
IL255179B (en) 2018-06-28
EP3034608B1 (en) 2019-01-30
RU2590594C2 (ru) 2016-07-10
HRP20160865T1 (hr) 2016-10-07
JP2017012204A (ja) 2017-01-19
CA2804311A1 (en) 2011-12-29
KR102506001B1 (ko) 2023-03-07
RU2016119423A3 (es) 2019-11-19
US9334333B2 (en) 2016-05-10
US20150351371A1 (en) 2015-12-10
CN103068993A (zh) 2013-04-24
US20190203171A1 (en) 2019-07-04
KR20230036157A (ko) 2023-03-14
US20150246977A1 (en) 2015-09-03
KR102462042B1 (ko) 2022-11-03
US10266803B2 (en) 2019-04-23
US20180064078A1 (en) 2018-03-08
KR20210013376A (ko) 2021-02-03
JP2021061863A (ja) 2021-04-22
IL269078A (en) 2019-11-28
US9540452B2 (en) 2017-01-10
ES2721749T3 (es) 2019-08-05
HK1168384A1 (zh) 2012-12-28
HUE030285T2 (en) 2017-05-29
JP2018201527A (ja) 2018-12-27
RU2724736C2 (ru) 2020-06-25
LT2905338T (lt) 2017-12-27
EP2905338B8 (en) 2018-01-24
PT2480675T (pt) 2016-07-11
DK2905338T3 (da) 2017-11-06
IL244450A (en) 2017-11-30
EP2905338B1 (en) 2017-08-02
IL291301B1 (en) 2023-03-01
ZA201300062B (en) 2014-09-25
HUE036597T2 (hu) 2018-07-30
KR20190073584A (ko) 2019-06-26
CY1118126T1 (el) 2017-06-28
KR20220150430A (ko) 2022-11-10
RS55037B1 (sr) 2016-12-30
RS54891B1 (sr) 2016-10-31
PL2905338T3 (pl) 2018-01-31
IL247386A (en) 2017-07-31
US9035128B2 (en) 2015-05-19
EP2905338A1 (en) 2015-08-12
CY1117537T1 (el) 2017-04-26
KR20210073609A (ko) 2021-06-18
KR101991234B1 (ko) 2019-06-20
US9163092B2 (en) 2015-10-20
US20150173331A1 (en) 2015-06-25
EP2568049B1 (en) 2016-04-13
US20170107484A1 (en) 2017-04-20
KR102320944B1 (ko) 2021-11-04
SI3034608T1 (sl) 2019-06-28
JP2019033765A (ja) 2019-03-07
IL259965B (en) 2019-02-28

Similar Documents

Publication Publication Date Title
MX348942B (es) Ratones que expresan una cadena ligera hibrida de inmunoglobulina.
AU2020277108B2 (en) Humanized universal light chain mice
IN2014DN08163A (es)
EP3839049A3 (en) Antibodies, variable domains & chains tailored for human use
MX346500B (es) Metodos y composiciones para inmunoterapia para enfermedad neural.
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
MX347515B (es) Agentes que se unen al receptor encrespado y usos de los mismos.
MY173363A (en) Mice that make heavy chain antibodies
MX368931B (es) Animales no humanos que tienen un gen de proteina reguladora de señal humanizado.
EP4218409A3 (en) Mice expressing a limited immunoglobulin light chain repertoire
IN2014MN01879A (es)
SG194466A1 (en) Non-human animals expressing antibodies having a common light chain
MX2012009168A (es) Raton de cadena ligera comun.
MY173936A (en) Humanized light chain mice field of invention
EP2331136A4 (en) FRIZZLED-BINDING SUBSTANCES AND ITS USES
MY156743A (en) Humanized fc?r mice
MX2015012540A (es) Ratón de cadena ligera común.
TH146784A (th) หนูที่แสดงออกสายเบาไฮบริดของอิมมูโนโกลบูลิน